Effects of nandrolone decanoate compared with placebo or testosterone on HIV‐associated wasting
- 23 February 2006
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 7 (3), 146-155
- https://doi.org/10.1111/j.1468-1293.2006.00358.x
Abstract
Objectives Current research is unclear about the most effective pharmacological agents for managing the loss of weight and fat-free mass common in HIV/AIDS. The aim of this study was to compare nandrolone decanoate with placebo and testosterone. Methods The study was a multicentre randomized double-blind placebo-controlled trial. Three hundred and three adult HIV-positive male patients with a weight loss of 5-15% in the last 12 months, or a body mass index of 17-19 kg/m(2), or a body cell mass/height ratio lower than 13.5 kg/m, were randomly assigned to receive nandrolone decanoate (150 mg), testosterone (250 mg) or placebo intramuscularly every 2 weeks for 12 weeks. Fat-free mass, weight, immune markers and perception of treatment were the main outcome measures. Results Treatment with nandrolone resulted in significantly greater increases in fat-free mass [mean increase 1.34 kg; 95% confidence interval (CI) 0.60; 2.08 kg] and in weight (mean increase 1.48 kg; 95% CI 0.82; 2.14 kg) compared with placebo. The mean increase in weight with nandrolone of 1.00 kg (95% CI 0.27; 1.74 kg) when compared with testosterone was significant, although the difference in fat free mass did not reach significance (mean increase 0.69 kg; 95% CI-0.13; 1.51 kg). Patient perception of benefit was significantly greater in the nandrolone group when compared with both the placebo and the testosterone groups. Conclusions Treatment with nandrolone decanoate increased body weight when compared with placebo and testosterone. Nandrolone decanoate treatment resulted in greater increases in fat-free mass than placebo and demonstrated a trend for a significant increase when compared with testosterone.Keywords
This publication has 31 references indexed in Scilit:
- Effects of Testosterone Administration on Fat Distribution, Insulin Sensitivity, and Atherosclerosis ProgressionClinical Infectious Diseases, 2003
- Weight Loss and Wasting in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2000
- Effects of Pharmacological Doses of Nandrolone Decanoate and Progressive Resistance Training in Immunodeficient Patients Infected with Human Immunodeficiency VirusJournal of Clinical Endocrinology & Metabolism, 1999
- Sustained Anabolic Effects of Long‐Term Androgen Administration in Men with AIDS WastingClinical Infectious Diseases, 1999
- Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wastingJournal of Clinical Endocrinology & Metabolism, 1996
- Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infectionAIDS, 1996
- Endocrine function in 98 HIV-infected patientsAIDS, 1991
- The effect of anabolic steroids on lean body mass: The dose response curveMetabolism, 1985